| What is RSS feed? | About Us |
 |
 Search Score: 5/10
Source: news.yahoo.com --- 22 hours ago
HealthDay - (HealthDay News) -- Here are the latest Clinical trials, courtesy of CenterWatch: ... Source: news.yahoo.com --- 22 hours ago
HealthDay - (HealthDay News) -- Here are the latest Clinical trials, courtesy of CenterWatch: ... Source: www.ncbi.nlm.nih.gov --- 2 hours ago
Related Articles Mammalian aquaporins: diverse physiological roles and potential Clinical significance. Expert Rev Mol Med. 2008;10:e13 Authors: Verkman AS Aquaporins have multiple distinct roles in mammalian physiology. Phenotype analysis of aquaporin-knockout mice has confirmed the predicted role of aquaporins in osmotically driven transepithelial fluid transport, as occurs in the urinary concentrating mechanism and glandular fluid secretion. Aquaporins also facilitate water movement into and out of the brain in various pathologies such as stroke, tumour, infection and hydrocephalus. A major, unexpected cellular role of aquaporins was revealed by analysis of knockout mice: aquaporins facilitate cell migration, as occurs in angiogenesis, tumour metastasis, wound healing, and glial scar formation. Another unexpected role of aquaporins is in neural function - in sensory signalling and seizure activity. The water-transporting function of aquaporins is likely responsible for these roles. A subset of aquaporins that transport both water and glycerol, the 'aquaglyceroporins', regulate glycerol content in epidermal, fat and other tissues. Mice lacking various aquaglyceroporins have several interesting phenotypes, including dry skin, resistance to skin carcinogenesis, impaired cell proliferation, and altered fat metabolism. The various roles of aquaporins might be exploited clinically by development of drugs to alter aquaporin expression or f ... Source: www.prweb.com --- 2 hours ago
CosmetaLife Clinical trial results could lead to availability of more natural, longer lasting, cost-effective treatment for deep lines and wrinkles by 2009. (PRWeb Jul 24, 2008) Read the full story at http://www.prweb.com/releases/clinical_trials/cosmetalife/prweb1138864.htm ... Source: pin.primate.wisc.edu --- 21 hours ago
Posted 2008-07-21 | ONPRC/OHSU ... Source: www.prnewswire.com --- 4 hours ago
... Source: www.businesswire.com --- 21 hours ago
SALT LAKE CITY--(BUSINESS WIRE)--BayCare Health System in the Tampa Bay region and PeaceHealth healthcare system, headquartered in Bellevue, Wash., have selected real-time electronic ... Source: www.marketwire.com --- 21 hours ago
MONTREAL (MARKET WIRE) TOPIGEN Pharmaceuticals Inc., a Clinical-stage biopharmaceutical company specialized in developing products for respiratory disorders, today announced the completion of patient enrollment in a Phase II safety and efficacy study in asthma with one of its lead product candidates, TPI ASM8. The current Clinical study builds on prior efficacy and safety data in a three-day study of TPI ASM8 in an allergen challenge model. TPI ASM8 is a novel, inhaled, anti-inflammatory drug in development for the management of moderate or severe asthma. ... Source: www.medicalnewstoday.com --- 1 day ago
This study investigates the effects of treatment with differing levels of propofol after haemorrhagic shock (HS) on conscious rats. HS is secondary to major blood loss and frequently precedes multiple organ failure, often resulting in death. A low dose of propofol (1mg/kg/hour) after HS suppressed increased levels of inflammatory cytokines and protected against HS-induced organ damages. ... Source: www.medicalnewstoday.com --- 14 hours ago
Culturally tailored health education appears to help improve some Clinical outcomes in the short-term for minorities with type 2 diabetes, according to a study published in the Cochrane Database of Systematic Reviews, Reuters Health reports. The study noted that language and cultural barriers can serve as obstacles to quality diabetes health education for minorities. ... Source: www.medicalnewstoday.com --- 14 hours ago
Targacept, Inc. (NASDAQ: TRGT), a Clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics™, today announced that it has initiated a Phase 2b Clinical trial of TC-5214 as an augmentation therapy in subjects with Major Depressive Disorder (MDD). TC-5214 is a broad spectrum neuronal nicotinic receptor (NNR) antagonist and represents a promising new mechanism in development for the treatment of MDD. ... Source: www.medicalnewstoday.com --- 15 hours ago
Hyperion Therapeutics, Inc. announced that it has completed patient enrollment in its Phase 1/2 Clinical trial to evaluate the safety, tolerability and ammonia scavenging effects of HPN-100 (formally called GT4P) versus BUPHENYL(R) (sodium phenylbutyrate) in patients with urea cycle disorders (UCD). The company plans to announce top-line results in the fourth quarter of this year. ... Source: www.medicalnewstoday.com --- 1 day ago
Tibotec Pharmaceuticals Ltd. announced that two major phase III efficacy trials examining TMC278, its investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in treatment-naive adults with HIV-1, are now recruiting patients. ... Source: www.jobster.com --- 21 hours ago
DISTINGUISHED CAREERS BEGIN HERE. When you become a Clinical laboratory scientist and an Officer on the U.S. Army Reserve Health Care Team, you'll be able to perform important research in your specialty. You'll be.. ... Source: www.jobster.com --- 22 hours ago
Job Description Care for patients and help them improve their quality of life by utilizing your Clinical experience and pharmacy training. Open positions in top hospitals, clinics and universities in the Fort Wayne, IN area. Board certified specialti ... Source: medical.bizcommunity.com --- 21 hours ago
“Every person who seeks care in a healthcare facility should expect to receive safe care that is delivered in a safe environment” Read full story... | Send to a friend ... Source: del.icio.us --- 12 hours ago
... Source: pharmalicensing.com --- 15 hours ago
Our client, an International Pharmaceutical Company, is looking for an Associate Director, Modelling & Simulation. You will act as the lead pharmacokineticist on international project teams, contributing to PK and M&S expertise at all phases of the drug development process, from Clinical introduction through to registration.You will be responsible for implementing M&S strategies, including design and analysis of (population) PK and PK/PD studies, as well as conducting PK and PK/PD data analysis, using methods across the spectrum from non-compartmental to population approaches.You will be a pharmacokineticist with demonstrable, hands-on experience in population PK/PD, Modelling and Simulation, using NONMEM and S-Plus / R, SAS, Matlab, WinBugs. You will also have experience with strategic application of modelling and simulation to drug development, gained within the pharmaceutical industry. You will hold a relevant higher degree.To apply, please contact Tim Wagstaff at RSA Pharmarecruit on 01707 280814 or email CV's to Tim.Wagstaff@theRSAgroup.com. Please note that only candidates with EU work authorisation will be considered. ... Source: www.healingwell.com --- 23 hours ago
COPD (Chronic Obstructive Pulmonary Disease) Tourette's Syndrome Healthy Patient Studies ... Source: pt.wkhealth.com --- 60 minutes ago
Page: 109 DOI: 10.1097/01.JCE.0000315046.39255.e6 Authors: Keil, Ode R. MS, MBA, CCE ... Find more results for Clinical on RSSMicro.com |
Copyright © 2008 RSSMicro.com
